Compare

IDEXX Laboratories vs IQVIA

MonkScore ranges and fundamentals, side by side

Key facts

IDEXX Laboratories and IQVIA: key facts

  • In fiscal 2025, IDEXX Laboratories, Inc. reported revenue of $4.3B and net income of $1.1B.
  • In fiscal 2025, IQVIA Holdings Inc. reported revenue of $16.3B and net income of $1.4B.
  • IDEXX Laboratories, Inc.'s revenue grew 7.6% a year from fiscal 2021 to fiscal 2025.
  • IQVIA Holdings Inc.'s revenue grew 4.1% a year from fiscal 2021 to fiscal 2025.
  • IDEXX Laboratories, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • IQVIA Holdings Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, IDEXX Laboratories, Inc. reported revenue of $4.6B and net income of $1.1B.
  • In the twelve months to 30 September 2026, IQVIA Holdings Inc. reported revenue of $17.3B and net income of $1.4B.

Side by side

IDEXX Laboratories and IQVIA, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureIDEXX Laboratories, Inc.NASDAQ:IDXXIQVIA Holdings Inc.NYSE:IQV
MonkScore
MonkScore range90–100as of October 202670–80as of October 2026
Sector rank1 of 628 in Healthcare153 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Latest fiscal year
Revenue$4.3BFY 2025$16.3BFY 2025
Net income$1.1BFY 2025$1.4BFY 2025
Free cash flow$1.1BFY 2025$2.1BFY 2025
Operating cash flow$1.2BFY 2025$2.7BFY 2025
Total debt$1.1BFY 2025$16.2BFY 2025
Cash$180.1MFY 2025$2.0BFY 2025
Last 12 months
Revenue$4.6Bto 30 June 2026$17.3Bto 30 September 2026
Net income$1.1Bto 30 June 2026$1.4Bto 30 September 2026
Free cash flow$1.3Bto 30 June 2026$2.1Bto 30 September 2026
Operating cash flow$1.4Bto 30 June 2026$2.7Bto 30 September 2026
Total debt$1.1Bto 30 June 2026$16.3Bto 30 September 2026
Cash$196.9Mto 30 June 2026$2.2Bto 30 September 2026

MonkStreet provides research, not investment advice.